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Abstract
Background: SARS-CoV-2 is the causative agent of COVID-19, an emergent zoonotic 
disease which has reached pandemic levels and is designated a public health 
emergency of international concern. It is plausible that former or current smoking 
status are associated with infection, hospitalisation and/or mortality from COVID-19.
Objective: We aimed to estimate the association of smoking status with rates of i) 
infection, ii) hospitalisation, iii) disease severity, and iv) mortality from SARS-CoV-
2/COVID-19.
Methods: We adopted recommended practice for rapid evidence reviews, which 
involved limiting the search to main databases and having one reviewer extract data 
and another verify. Published articles and pre-prints were identified via Ovid MEDLINE, 
medRxiv and expertise within the review team. We included observational studies with 
community-dwelling or hospitalised adults aged 16+ years who had been tested for 
SARS-CoV-2 infection or diagnosed with COVID-19, providing that data on smoking 
status were reported. T he National Institutes of Health’s Quality Assessment T ool for 
Observational Cohort and Cross-Sectional Studies was used to divide studies into 
‘good’, ‘fair’ and ‘poor’ quality. Studies were judged as ‘good’ quality if they: i) had low 
levels of missing data on smoking status, ii) used a reliable self-report measure that 
distinguished between current, former and never smoking status iii) used biochemical 
verification of smoking status and iv) adjusted analyses for potential confounding 
variables.
Results: Forty-one studies were included, 25 of which were conducted in China, seven 
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in the US, three in France, two across multiple international sites and one each in the 
UK, Korea, Mexico and Spain. Nine studies did not state the source for information on 
smoking status. T hirty-one studies reported current and/or former smoking status 
but had high levels of missing data and/or did not explicitly state whether the 
remaining participants were never smokers. Notwithstanding recording uncertainties, 
compared with national prevalence estimates, recorded current and former smoking 
rates in 36 (5 ‘fair’ and 31 ‘poor’ quality) studies of hospitalised patients were generally 
lower than expected. In two ‘fair’ quality studies, current and former smokers 
appeared more likely to be tested for SARS-CoV-2 but there was no difference in the 
risk of testing positive in current (RR = 0.74, 95% CI = 0.31-1.73, p = .49) or former (RR 
= 1.18, 95% CI = 0.82-1.69, p = .37) compared with never smokers. In three ‘fair’ quality 
studies of people who tested positive in the community, there was no evidence for a 
decreased risk of hospitalisation among current (RR = 0.95, 95% CI = 0.76-1.18, p = 
.62) or former (RR = 1.04, 95% CI = 0.98-1.10, p = .26) smokers compared with never 
smokers. In three ‘fair’ quality studies, there was an increased risk of greater disease 
severity in hospitalised current (RR = 1.36, 95% CI = 1.07-1.74, p = .01) but not former 
(RR = 1.51, 95% CI = 0.86-2.65, p = .15) smokers compared with never smokers. T wo 
‘poor’ quality studies provided mixed evidence for the risk of death in current 
compared with former/never smokers.
Conclusions: Across 41 observational studies, there is substantial uncertainty about 
the associations between smoking and COVID-19 outcomes arising from the 
recording of smoking status. T he recorded smoking prevalence in hospitalised 
patients across multiple settings was lower than national estimates but that 
observation is inconsistent with there being no evidence of increased admission to 
hospital from three ‘fair’ quality studies among people who tested positive in the 
community. T here was limited evidence from ‘fair’ quality studies that current 
compared with never smoking is associated with greater disease severity in those 
hospitalised for COVID-19.
Implications: Unrelated to COVID-19, smokers are at a greater risk of a range of 
serious health problems requiring them to be admitted to hospital. Given uncertainty 
around the association of smoking with COVID-19, smoking cessation remains a public 
health priority and high-quality smoking cessation advice should form part of public 
health efforts during this pandemic.
Introduction
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COVID-19 is a respiratory disease caused by the emerging SARS-CoV-2 virus. Large age
and gender differences in case severity and mortality have been observed in the ongoing
COVID-19 pandemic1; however, these differences are currently unexplained. SARS-CoV-2
enters epithelial cells through the ACE2 receptor2. Some evidence suggests that gene
expression and subsequent receptor levels are elevated in the airway and oral epithelium
of current smokers3,4, thus putting smokers at higher risk of contracting SARS-CoV-2.
Other studies, however, suggest that nicotine downregulates the ACE2 receptor5. T hese
uncertainties notwithstanding, both former and current smoking is known to increase the
risk of respiratory viral6,7 and bacterial8,9 infections and is associated with worse
outcomes once infected. Cigarette smoke reduces the respiratory immune defence
through peri-bronchiolar inflammation and fibrosis, impaired mucociliary clearance and
disruption of the respiratory epithelium10. T here is also reason to believe that
behavioural factors (e.g. regular hand-to-mouth movements) involved in smoking may
increase SARS-CoV-2 infection and transmission in current smokers. However, early data
from the COVID-19 pandemic have not provided clear evidence for a negative impact of
current or former smoking on SARS-CoV-2 infection or COVID-19 disease outcomes,
such as hospitalisation or mortality11. It has also been hypothesised that nicotine might
protect against a hyper-inflammatory response (or “cytokine storm”) to SARS-CoV-2
infection, which may lead to adverse outcomes in patients with COVID-19 disease12.
 
T here are several reviews that fall within the scope of smoking and COVID-1911,13–17.
We aimed to produce a rapid synthesis of available evidence pertaining to the rates of
infection, hospitalisation, disease severity and mortality from SARS-CoV-2/COVID-19
stratified by smoking status. Given the increasing availability of data on this topic, this will
be a ‘living’ review with fortnightly updates. As evidence accumulates, the review will be
expanded to include studies reporting outcomes by alternative nicotine use (e.g., nicotine






We adopted recommended practice for rapid evidence reviews, which involved limiting
the search to main databases and having one reviewer extract the data and another
verify18.
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Eligibility criteria
 
Studies were included if they:
 
1)      Were primary research studies using experimental (e.g. randomised controlled trial),
quasi-experimental (e.g. pre- and post-test) or observational (e.g. case-control) study
designs;
2)      Involved as participants adults aged 16+ years;
3)      Recorded as outcome i) results of a SARS-CoV-2 diagnostic test (including antibody
assays), ii) a clinical diagnosis of COVID-19, iii) hospitalisation for COVID-19, iv) severity of
COVID-19 disease or v) mortality from COVID-19;
4)      Reported any of the outcomes of interest by self-reported or biochemically verified
smoking status (e.g. current smoker, former smoker, never smoker);
5)      Were available in English;
6)      Were published in a peer-reviewed journal, as a pre-print or a public health report by




T he following terms were searched for in Ovid MEDLINE as free text or Medical Subject
Headings:
 
1.       T obacco Smoking/ or Smoking Cessation/ or Water Pipe Smoking/ or Smoking/ or
Smoking Pipes/ or Cigar Smoking/ or Smoking Prevention/ or Cigarette Smoking/ or
smoking.mp. or Pipe Smoking/ or Smoking, Non-T obacco Products/ or Smoking Water
Pipes/
2.       Nicotine/ or nicotine.mp. or Electronic Nicotine Delivery Systems/ or Nicotine
Chewing Gum/
3.       vaping.mp. or Vaping/
4.       1 or 2 or 3
5.       Coronavirus/ or Severe Acute Respiratory Syndrome/ or Coronavirus Infections/ or
covid.mp.
6.       4 and 5
 
T he following terms were searched for in titles, abstracts and full texts in medRxiv:
 
1.       covid smoking
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2.       covid nicotine
3.       covid vaping
 
Additional articles/reports of interest were identified through mailing lists, T witter, the
International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), the
Intensive Care National Audit & Research Centre (ICNARC) and the US Centers for








Data were extracted by one reviewer and verified by a second on i) author (year); ii) date
published; iii) country; iv) study design; v) study setting; vi) sample size; vii) sex; viii) age; ix)
smoking status (e.g. current, former, never, missing); x) SARS-CoV-2 infection; xi)





T he National Institutes of Health’s Quality Assessment T ool for Observational Cohort
and Cross-Sectional Studies was used to determine the quality (i.e. ‘good’, ‘fair’, ‘poor’) of
included studies (19). Studies were judged as ‘good’ quality if they: i) had low levels of
missing data on smoking status, ii) used a reliable self-report measure that distinguished
between current, former and never smoking status iii) used biochemical verification of
smoking status; and iv) adjusted analyses for potential confounding variables (e.g. age,
comorbidities). Studies were rated as ‘fair’ if they had low levels of missing data on
smoking status and did one of either: i) used a reliable measure of current, former and
never smoking status (e.g. self-report); or ii) adjusted analyses for potential confounding
variables. Studies were otherwise rated as ‘poor’. T he quality appraisal was conducted by




A narrative synthesis was conducted. Where possible, data were pooled in RevMan
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v.5.320 with the Mantel–Haenzel or inverse variance method using random or fixed
effects, depending on heterogeneity, and presented as risk ratios (RRs)21. Heterogeneity





A total of 115 records were identified, of which 58 full texts were screened, 41 studies





Characteristics of included studies are presented in T able 1. T wenty-five studies were
conducted in China1,23,32–41,24,42–47,25–31, seven in the US48–54, three in France55–57, two
multi-site international studies58,59 and one each from the UK60, Mexico61, Korea62 and
Spain63. T hirty-five studies were conducted in hospital settings. Seven studies included a
community component in addition to hospitalised patients48,49,54–56,60. Studies had a
median of 368 (interquartile range = 66-1,000) participants. T he total sample analysed in
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T he levels used to categorise smoking status were heterogeneous (see T able 1). Nine
studies did not report the source for information on smoking status. Notably, only six
studies recorded current, former and never smoking status, with a further four studies
reporting current or current/former and never smoking status. T he remaining 31 studies
reported current and/or former smoking status but did not explicitly state whether the
remaining participants were never smokers or whether data on smoking status were
missing. Nine studies explicitly reported missing data on smoking status, which ranged
from 1.3% to 92% (weighted mean = 33%). Smoking status was predominantly collected
through routine electronic health records. T welve studies used a bespoke case report
form for COVID-19. None of the studies verified smoking status biochemically. T wo
studies26,40 specifically stated that smokers were those with a >30 pack-year history or a
greater than 20-year history of smoking, respectively. Most studies did not assess
tobacco exposure (e.g. pack-years of smoking) in current or former smokers, or time
since quitting in former smokers.
 
Smoking prevalence among those with SARS-CoV-2 infection or a COVID-19 diagnosis by
country
 
In the included studies conducted in hospital settings across China, 3.8% to 17.6% were
current smokers and 1.9% to 5.0% (missing = 1.2%-92.0%) were former smokers.
However, current and former smoking prevalence in China was reported to be 50.5% and
8.4% respectively among men and 2.1% and 0.8% respectively among women in 201864,
thus suggesting lower than expected proportions of current and former smokers in the
included studies.
 
In the studies conducted in the US across community and hospital settings, 1.3% to
27.2% were current smokers and 2.3% to 30.6% (missing = 5.3%-96.4%) were former
smokers. T his compares with a prevalence of 13.8% current and 20.9% former smokers
in the US in 201865.
 
In the studies conducted in France, 7.1% to 10.4% were current smokers and 18.0% to
59.1% (missing = 1.9%) were former smokers across community and hospital settings.
T his compares with a current and former smoking prevalence of 32.0% and 31.4%
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respectively in France in 201866, thus suggesting a lower than expected proportion of
current smokers in the included studies but a higher than expected proportion of former
smokers in one study.
 
In one of the multi-site studies with participants predominantly from hospital settings in
the UK, 4.7% were ever smokers (missing = 47.0%). In the study conducted in the UK,
10.0% were current smokers and 34.6% were former smokers (missing = 0.6%). T his
compares with a current and former smoking prevalence of 14.4% and 25.8% in England
in 201867, thus suggesting a lower than expected proportion of current and former
smokers in the multi-site study but a higher than expected proportion of former smokers
in the UK only study.
 
In the study conducted within the healthcare service in Mexico, 9.4% were current
smokers (missing = 90.6%). T his compares with a national smoking prevalence of 16.6%
in Mexico in 201568.
 
In the study conducted in a hospital setting in Spain, 42.9% were ever smokers (missing =
0.0%). T his compares with a national ever smoking prevalence of 51.3% in Spain in
200869.
 
In the study conducted in a hospital setting in Korea, 18.5% were current smokers
(missing = 82.1%). T his compares with a national smoking prevalence of 19.3% in Korea
in 201670.
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SARS-CoV-2 infection by smoking status
 
One ‘poor’ and two ‘fair’ quality studies provided data on SARS-CoV-2 test results for
people meeting local testing criteria by smoking status (see T able 2). In the ‘poor’ quality
study with data from high school students, school-based staff, parents and siblings in
France56, current smokers (7.2%) were less likely to test positive than never smokers
(28.0%) (RR = 0.26, 95% CI = 0.11-0.61, p < .002).
 
In a cohort study of US military veterans aged 54-7548, current smokers were more likely
to receive a test: 42.3% (1,603/3,789) of the sample were current smokers compared
with 23.8% of all veterans aged 50+ years using any tobacco product between 2010-
201571. Current smokers (RR = 0.48, 95% CI = 0.40-0.58, p < .001) but not former
smokers (RR = 0.98, 95% CI = 0.82-1.17, p = .80) had a significantly reduced risk of testing
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positive compared with never smokers.
 
In the UK Biobank cohort60, former smokers (RR = 1.29, 95% CI = 1.14-1.45, p < .001)
and current smokers (RR = 1.44, 95% CI = 1.20-1.71, p < .001) were more likely to be
tested compared with never smokers in a multivariable analysis. However, former
smokers (RR = 1.42, 95% CI = 1.18-1.70, p < .001) but not current smokers (RR = 1.15,
95% CI = 0.86-1.54, p > .05) had greater risk of testing positive compared with never
smokers.
 
Meta-analyses were performed for the two ‘fair’ quality studies. No significant difference
was observed between current and never smokers (RR = 0.74, 95% CI = 0.31-1.73, p =
.49) or former and never smokers (RR = 1.18, 95% CI = 0.82-1.69, p = .37) in the risk of
testing positive for SARS-CoV-2 (see Figure 2 and 3, respectively).
 
Figure 2. Forest plot for risk of testing positive for SARS-CoV-2 in current vs. never smokers
 
Figure 3. Forest plot for risk of testing positive for SARS-CoV-2 in former vs. never smokers.
 
Hospitalisation for COVID-19 by smoking status
 
Five studies examined hospitalisation for COVID-19 disease stratified by smoking status
(see T able 3). Meta-analyses were performed for three ‘fair’ quality studies. T here was
no significant difference between current and never smokers (RR = 0.95, 95% CI = 0.76-
1.18, p = .62) or former and never smokers (RR = 1.04, 95% CI = 0.98-1.10, p = .26) in the
risk of requiring admission to hospital following diagnosis of COVID-19 (see Figure 4 and
5, respectively).
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Figure 4. Forest plot for risk of hospitalisation in current vs. never smokers.
Figure 5. Forest plot for risk of hospitalisation in former vs. never smokers.
 
Disease severity by smoking status
 
T hirteen studies reported disease severity in hospitalised patients stratified by smoking
status (see T able 4). Severe (as opposed to non-severe) disease was broadly defined as
requiring IT U admission, requiring oxygen as a hospital inpatient or in-hospital death
(where this had not been disaggregated into disease severity vs. mortality). Meta-
analyses were performed for three ‘fair’ quality studies. Current smokers were at
increased risk of greater severity disease compared with never smokers (RR = 1.36, 95%
CI = 1.07-1.74, p = .01). No significant difference was observed between former and
never smokers (RR = 1.51, 95% CI = 0.86-2.65, p = .15) (see Figure 6 and 7, respectively).
 
Figure 6. Forest plot for the risk of severe disease in current vs. never smokers.
Figure 7. Forest plot for the risk of severe disease in former vs. never smokers.
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Mortality by smoking status
 
Five studies reported mortality from COVID-19 by smoking status (see T able 5), with two
‘poor’ quality studies reporting multivariable analyses58,63. One reported increased odds
of in-hospital death in current compared with former/never/unknown smokers (OR =
1.79, 95% CI = 1.29-2.47, p < .001) and the other reported no significant difference in
mortality between current and former/never/unknown smokers (HR = 1.05, 95% CI =




Quality ratings for the included studies are presented in T able 6. Seven studies were rated
as ‘fair’ quality due to having low levels of missing data and either i) distinguished between
current, former and never smoking status or ii) adjusted analyses for potential
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T his rapid review of 41 observational studies found substantial uncertainty arising from
the recording of smoking status. Notwithstanding recording uncertainties, compared
with national prevalence estimates, recorded current and former smoking rates in 36
studies of hospitalised patients (of which five were of ‘fair’ quality) were generally lower
than expected. From available data, there was insufficient evidence to establish whether
current and/or former smoking status is associated with SARS-CoV-2 infection,
hospitalisation or mortality. T here was limited evidence from ‘fair’ quality studies that
disease severity in those hospitalised for COVID-19 is greater in current but not former
smokers compared with never smokers.
 
Infection by smoking status
 
Current and former smokers in the community appear more likely to receive a test. It
should be noted that current smokers may be more likely to meet local criteria for
community testing due to increased prevalence of symptoms consistent with SARS-CoV-
2 infection, such as cough and increased sputum production. However, there was no
difference in the risk of testing positive in current or former compared with never
smokers.
 
Hospitalisation and disease severity by smoking status
 
As reported elsewhere, smoking prevalence among multiple hospital cohorts was
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consistently lower than national estimates16. In contrast, there was no evidence that
current or former smokers are at lower risk of hospitalisation for COVID-19 compared
with never smokers among those identified as testing positive in the community. T here
was some limited evidence that current smokers are at increased risk of greater disease
severity compared with never smokers.
 
However, these early studies are limited by several factors. First, most studies relied on
electronic health records (EHRs) as the source of information on smoking status.
Research shows large discrepancies between EHRs and actual behaviour72. Known
failings of EHRs include implausible longitudinal changes, such as former smokers being
recorded as never smokers at subsequent hospital visits72. Misreporting on the part of
the patient (perhaps due to perceived stigmatisation) has also been observed, with
biochemical measures showing higher rates of smoking behaviour compared with self-
report in hospitalised patients in the US73. It is hence likely that substantial under-
reporting of current and former smoking status has occurred across the included
studies. Second, individuals with severe symptoms from COVID-19 may have stopped
smoking prior to admission to a care facility and may therefore not have been recorded
as current smokers (i.e. reverse causality). T hird, smokers with COVID-19 may be less
likely to present to hospital because of lack of access to healthcare and more likely to die
in the community from sudden complications (i.e. self-selection). T aken together, these
may explain the observation that smoking prevalence has been consistently lower than
expected in hospitalised cohorts, without invoking a protective effect of smoking. In
contrast, it is not clear how these biases could lead to the associations between under-
reported smoking status and greater disease severity among those hospitalised. If there
is a true negative effect and the 'missing smokers' arise from biases, then the observed
association among those hospitalised would be deflated by those people being classified
as never smokers or missing from hospital. On the other hand, if there is a protective
effect of nicotine, then abrupt nicotine withdrawal upon hospitalisation may lead to worse
outcomes12. Fourth, it should also be noted that smoking is a risk factor for both
hypertension and diabetes, two diseases associated with worse outcomes from COVID-
19, which suggests that current and former smoking may be both directly and indirectly
implicated in COVID-19 outcomes. Last, reason for hospitalisation varies by country and
time in the epidemic. For example, initial cases may have been hospitalised for isolation
and quarantine reasons and not due to medical necessity. It is plausible that this may
have skewed early data towards less severe cases.
 
Mortality by smoking status
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T wo ‘poor’ quality studies provided mixed evidence for the risk of death in current
compared with former/never smokers. It should also be noted that these early studies




T his rapid review was limited by not having two independent reviewers extracting data,
limiting the search to one electronic database and one pre-print server and not including
at least two large population surveys due to their reliance on self-reported SARS-CoV-2
infection (which hence means they are not currently meeting our eligibility criteria)74,75.
Population surveys – particularly with linked health data – will be included in future review
versions to help mitigate some of the limitations of healthcare based observational
studies.
 
Implications for research, policy and practice
 
Further research is needed to resolve the mixed findings summarised in our review. A
priority study would be a large, representative population survey with a validated
assessment of smoking status which distinguishes between recent and long-term ex-
smokers – ideally biochemically verified – and assesses seroprevalence and links to health
records. In the meantime, public-facing messages about the possible protective effect of
smoking or nicotine are premature. In our view, until there is further research, the quality
of the evidence does not justify the huge risk associated with a message likely to reach
millions of people that a lethal activity, such as smoking, may protect against COVID-19.
It continues to be appropriate to recommend smoking cessation and emphasise the role
of alternative nicotine to support smokers to stop as part of public health efforts during
COVID-19. At the very least, smoking cessation reduces acute risks from cardiovascular
disease and could reduce demands on the healthcare system76. GPs and other
healthcare providers can play a crucial role – brief, high-quality and free online training is




Across 41 observational studies, there is substantial uncertainty arising from the
recording of smoking status on whether current and/or former smoking status is
associated with SARS-CoV-2 infection, hospitalisation or mortality. T here is limited
Qeios, CC-BY 4.0   ·   Article, May 7, 2020
Qeios ID: UJR2AW.3   ·   https://doi.org/10.32388/UJR2AW.3 16/23
evidence that current smoking compared with never is associated with greater disease
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